Enovis Co. (NYSE:ENOV) Shares Sold by Principal Financial Group Inc.

Principal Financial Group Inc. reduced its stake in shares of Enovis Co. (NYSE:ENOV) by 0.8% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 129,174 shares of the company’s stock after selling 1,005 shares during the period. Principal Financial Group Inc. owned 0.23% of Enovis worth $5,668,000 as of its most recent SEC filing.

Other institutional investors have also recently modified their holdings of the company. UMB Bank n.a. raised its position in shares of Enovis by 128.2% during the 4th quarter. UMB Bank n.a. now owns 778 shares of the company’s stock worth $34,000 after purchasing an additional 437 shares during the last quarter. Pinnacle Bancorp Inc. raised its position in shares of Enovis by 54.5% during the 4th quarter. Pinnacle Bancorp Inc. now owns 850 shares of the company’s stock worth $37,000 after purchasing an additional 300 shares during the last quarter. DekaBank Deutsche Girozentrale acquired a new position in shares of Enovis during the 3rd quarter worth approximately $55,000. FMR LLC raised its holdings in Enovis by 20.5% in the 3rd quarter. FMR LLC now owns 2,840 shares of the company’s stock valued at $122,000 after acquiring an additional 484 shares during the last quarter. Finally, XTX Topco Ltd acquired a new position in Enovis in the 3rd quarter valued at $217,000. 98.45% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, Needham & Company LLC cut their price target on Enovis from $65.00 to $64.00 and set a “buy” rating for the company in a report on Thursday, February 27th.

Enovis Trading Down 2.1 %

Shares of ENOV opened at $37.83 on Tuesday. The stock has a fifty day moving average of $44.72 and a two-hundred day moving average of $44.28. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.12 and a current ratio of 2.27. The company has a market capitalization of $2.15 billion, a PE ratio of -17.27 and a beta of 1.94. Enovis Co. has a fifty-two week low of $37.60 and a fifty-two week high of $63.96.

Enovis (NYSE:ENOV) last issued its quarterly earnings results on Wednesday, February 26th. The company reported $0.98 earnings per share for the quarter, beating the consensus estimate of $0.92 by $0.06. Enovis had a positive return on equity of 4.39% and a negative net margin of 5.95%. The company had revenue of $560.98 million during the quarter, compared to the consensus estimate of $555.14 million. As a group, analysts forecast that Enovis Co. will post 2.79 EPS for the current year.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.